Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter DrugInvestors Business Daily • 02/06/25
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025PRNewsWire • 02/06/25
Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 02/04/25
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug ApprovalSeeking Alpha • 02/04/25
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial ResultsPRNewsWire • 01/30/25
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 ReleaseZacks Investment Research • 01/29/25
Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in AdultsPRNewsWire • 01/28/25
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)PRNewsWire • 01/27/25
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and DevicePRNewsWire • 01/23/25
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & MetabolismPRNewsWire • 01/21/25
Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist PortfolioGlobeNewsWire • 01/14/25
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & MetabolismPRNewsWire • 01/08/25
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/06/25
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal HyperplasiaPRNewsWire • 12/20/24
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And GrowthSeeking Alpha • 12/18/24
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal HyperplasiaPRNewsWire • 12/13/24
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) CapsulesPRNewsWire • 11/07/24
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) CapsulesPRNewsWire • 11/04/24
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive DyskinesiaPRNewsWire • 11/04/24